Bispecifics galore! Finding new ways to raise the bar in aggresive lymphomas and myeloma
A review of 14 early stage developments coming soon at ASH24
Are we searching for treasure and seeing a mirage?
As oncology products are flocking to autoimmune diseases, how is the landscape evolving?
The route to success is often a winding track with unexpected obstacles
When the future of ADCs and bispecifics collide
What's hot amongst the up and coming CAR-T cell therapies in early development?
Will 2024 be a 'Zeitenwende' moment for the IO field..
Small molecule and ADC standouts – a guest post
Which Thunderbirds are Go in this niche?!
The best marketing cannot solve a major product weakness in your compound
A smorgasbord of bispecifics and CAR-T cells for autoimmune diseases
On shiny lures and rose tinted glasses blinding reality
For all the breathless hype and attention focused on antibody-drug conjugates (ADCs) of late, you might…
When everyone zigs – zag!
On biomarkers, acquired resistance and immune escape, oh my!
7 early stage developments to watch out for at ESMO24
Why what we don't know might kill a few cancer programs
Are there hideen treasures in Yokohama, Japan
Not all ADC paths are paved with gold
A look atfive recent developments and what we can learn from them
Early stage oncology new product development is a rather strange beast at times. On the one hand is the…
How pivoting therapy areas might make a real impact for several refractory diseases
Teasing out relevant markers and learning more about what patients tumours are telling us is key
When CAR-T and bispecifics create a crowded competitive landscape
What's looking interesting in early stage trials at ASCO24?
Will new developments in tackling cytokines fare better in the clinic than the first generation attempts?
Can a new generation of bispecifics change our mind about a particular target?
When the going gets tough, the tough get going...
Sometimes oncology new product development can be fascinating to watch from the sidelines. There are…
In 2011 we did an annual ASCO highlight video reel of what to watch out for. Three phase 1…
The good, the bad, and the ugly under belly of the next flurry of ADCs
Where we look at half a dozen emerging agents and put them through their paces
It's time to look to the future beyond plain vanilla ADCs
Winners and losers at JPM24
Next generation CAR-T cells are coming to the clinic in 2024
10 IO topics to watch out for at ASH23
How a competitive landscape can change drastically over a short time
A look at the potential missing piece in making bispecifics even better
Eight key areas to watch out for at SITC 2023!
After a long wait, finally some encouraging data in advanced solid tumours!
There's a huge surge in ADCs in the clinic but how many will make an impact?
Parsing cancer research hype at ESMO23
A look at some hot topics from the TARGETS/TRIPLE meeting in Boston
From CAR-T cells to protein degradation
What we can learn from scientific talks at WCLC in order to improve clinical development
Early-stage agents in development for multiple myeloma - hit or miss?
Challenges and opportunities in the myeloma niche
Part 2 of our WCLC 2023 Previews
Some perspectives on the balancing act required between stimulus and response
When an established concept is finally coming of age with new colours...
Highlighting some outstanding research to take note of
Where a forgotten costimulator may hold the key to new developments
What do three phase 1 and one phase 2 trials tell us about future development?
Some ASCO23 abstracts to watch out for and why
Off the beaten track can bring danger and delight in the unknown in equal measure
Update on Developmental Therapeutics
Where we explain what to look for in 10 posters presented at AACR23
A look at some early stage ADC molecules in the clinic
Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…
As we continue our new products journey evaluating early stage agents in development with data at…
Improving cell therapy performance with a multitude of innovative strategies
What will be the emerging products and regimens to watch out for in aggressive lymphomas?
How can performance of T cell therapy be improved?
The evolving BMS-Celgene pipeline and what's coming next in new developmental twists
How novel bispecifics might help potentiate the impact of KRAS inhibitors when combined with checkpoint blockade
Ten emerging development areas to watch out for in oncology during 2023
The importance of T cell exhaustion and exploring ways to avoid it
10 early stage IO biotechs to watch out for
Half a dozen key posters to watch out for in early stage oncology at SITC22
Five areas of early stage IO developments to watch out for
Where is the TPD field likely headed with next generation approaches?
Bispecifics come and bispecifics go as companies seek to find a balance
An in-depth look at some of the issues impacting Amgen's pivotal trial and what it means for their competitors
In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…
What to watch out for in colorectal cancer, cholangiocarcinoma and hepatocellular carcinoma
A look at promising new approaches in SCLC
Where five different targeted therapies are put through their paces
When cell therapies and targeted therapies collide
Five key areas to watch out for at ASCO22
Can NK cells help checkpoint blockade work more effectively?
Looking beyond the hype from a broader perspective
Everything you needed to know about bispecifics at AACR22 and more!
5 areas to watch out for on the bispecific antibody front
The latest on bispecifics and protein degraders
Can a different twist on modality make a real difference and go beyond what we already have?
Several controversies abound in the CAR-T cell niche this year, plus what's coming next?
Finessing oncology targets can be both tricky and challenging. Does changing the modality help?
Sometimes we learn more from failure than we do from success
With SITC fast coming up this week, immunotherapies in all sorts of shapes and guises are very much…
Update on the various runners and riders in the TIGIT niche
SITC 2021 Preview
Key learnings and highlights from the recent AACR DLBCL specialist meeting
One of the things that struck me at this year’s ESMO conference was the sheer variety and richness…
A hard look at some IO agents in early development at ESMO21
What's hot at WCLC21?
Is it a marker or a target? Actually, what is the target - and why does it matter?
A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences
What are Gritstone up to behind the scenes and where are they headed in the near-term?
Update on the T cell engager niche with an emerging agent of interest
A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer
Who's going to the masquerade ball and how might they fare in the future?
13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies
13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?
A rock around the bispecific clock highlighting key presentations coming at the AACR 2021 virtual meeting
Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!
Gems from the WCLC20 poster hall which may make an impact
A look at the exon 20 insertion landscape - all to play for!
Important developments on the GI cancer front to watch out for
A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?
Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?
A critical look at the early stage BMS oncology pipeline
Commentary on engineered NK cells, including CAR-NK and memory-like NK cells
Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?
What caught our attention on novel bispecific antibodies at ASH20?
Updated look at the bispecific landscape in early clinical development
How we can learn more from failure in clinical trials so we can improve outcomes further with emerging agents in early development
Winners, losers and risers... who goes where in the final analysis?
What to watch out for this weekend in targeted therapies and early stage new product development
Five IO areas in early stage development to watch out for at ESMO20
Can we predict the future cancer drug combinations from emerging new targets?
If we were to tackle CAR T cell therapy design differently, how would we go about doing it?
The ups and downs of CAR-T cell therapy development continues apace
Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?
A look at some novel and promising approaches in early oncology new product development
An update on the CD20 x CD3 bispecific with expert commentary on data at ASCO EHA.
Ten intriguing novel agents in early development to watch out for
When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?
A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead
A look at some of the highly ranked clinical data presented over the weekend in Orlando
Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19
If we want to improve on the current results with IO therapies then we need to go to basics and understand the biology of each disease subset in the context of what we've learned so far
What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?
Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess
We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?
How the design of different cancer approaches can affect clinical performance
Round-up and analysis of key lymphoma data at iCML 2019
Highlights (and lowlights) from Day 2 of immunotherapy presentations at CIMT 2019 in Mainz.
A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.
Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.
Update on T cell bispecifics and other key topics in early stage IO development
An upcoming small biotech focused on IO targets with their novel platform approach
Some examples of potentially useful biomarker inclusion in early oncology trials
What to watch out for at the ASCO GI19 conference in San Francisco
Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy
FDA slaps a partial clinical hold for unwanted side effects, now what?
Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!
We offer 13 key highlights from day 2 of ASH18, including some surprises.
From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?
An extensive round-up of what to expect from SITC18 ahead of the abstract reveal
Lessons learned from recent failure and a look at where a few new developments might be coming from...
Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies
Update on BCMA, SLAMF7 and other targets in multiple myeloma
Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?
Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.
How do we drive more T cells into the tumour? Here's one company who are looking to do just that.
A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences
A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field
With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?
A look at the Class of 2018 new products in development - a hit or miss?
Jumpstarting the immune system with a synthetic immunity approach - how can we do this?
How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.
Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...
A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade
With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.
The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...
In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.
A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.
The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?
